Eyes on #NTLA:
1️⃣ NTLA-2002's Phase 2 for HAE has full patient rosters, prepping for a Q3 2024 Phase 3 launch—swift moves! #CRISPR

2️⃣ IND application for NTLA-2001 slated for September, could redefine ATTR amyloidosis treatment by year-end. #Investment

3️⃣ NTLA-3001 aims to quash Alpha-1 Antitrypsin Deficiency, single-dose style. Bye weekly IVs! #ClinicalTrials Dive deeper; each tier has something to grip your portfolio's attention. #fintoot